TME Pharma first-half 2026 net loss narrows 76% to EUR 507,000
Bitget2026/10/30 16:55- TME Pharma’s first-half 2026 net loss narrowed 76% year over year to EUR 507,000.
- Research and development expenses dropped 98% to EUR 21,000, while general and administrative expenses fell 79% to EUR 203,000.
- Operating cash outflow declined 71% to EUR 831,000; cash and cash equivalents totaled EUR 1.02 million at June 30.
- An October 29 exclusive negotiation agreement with TMS covers worldwide NOX-A12 rights and includes a EUR 150,000 non-refundable fee.
- Debtholders agreed in October to extend debt maturity to June 2028; new bond financing totaled EUR 750,000.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
